Form 4: Eli Lilly Executive Ilya Yuffa Reports Stock Transactions

Eli Lilly's EVP and President of International, Ilya Yuffa, reported the acquisition of 3,702 shares and the disposal of 1,664 shares of common stock on February 1, 2024.

Summary

• Ilya Yuffa, an Executive Vice President at Eli Lilly, reported transactions involving the company's common stock.
• On February 1, 2024, Yuffa acquired 3,702 shares of common stock through the vesting of restricted stock units.
• Also on February 1, 2024, Yuffa disposed of 1,664 shares of common stock at a price of $645.61 per share.
• Following these transactions, Yuffa directly owns 15,012 shares of Eli Lilly common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock transactions by an executive, which is neither positive nor negative in itself.

Industry Context

This is a routine disclosure of stock transactions by a company executive, which is common practice for publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and Eli Lilly's filing is consistent with these requirements.
• The transactions are typical for executives who receive stock-based compensation, such as restricted stock units, which vest over time.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine and do not indicate a change in the company's fundamentals.

Key Dates

Keywords

Eli Lilly, LLY, stock transaction, insider trading, Form 4, restricted stock units, executive compensation